首页/数据集/Thrombopoietin (TPO) protects against heart damage induced by doxorubicin and infarction in rat models

Thrombopoietin (TPO) protects against heart damage induced by doxorubicin and infarction in rat models

ChEBI2010-12-29 更新2026-07-21 收录

心脏损伤保护

临床前药效评价

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-15449 数据链接链接失效反馈

官方服务：

资源简介：

Thrombopoietin (TPO) protects against heart damage induced by doxorubicin and infarction in rat models

应用场景：

创建时间：

2010-12-29

临床前药效评价

皮下给药药代动力学

Anagrelide (ANA) is a phosphodiesterase 3A (PDE3A) inhibitor, commonly prescribed for essential thrombocythemia. It also functions as a molecular glue, inducing complex formation between PDE3A and Sch

DataCite Commons2025-05-12 更新320

Table 1 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas

神经肿瘤靶向治疗

临床前药效评价

The relative response of AG-NF2-Luc2 tumor xenografts in mice prior to and after treatment with vehicle, brigatinib, INK128, or brigatinib + INK128.

Figshare2026-01-27 更新40

Validation of a New Scoring Scale for Behavioral Assessment of L‑Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development

临床前药效评价

帕金森病异动症模型

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated nonhuman primate (NHP) has been described as the most translatable model for experimental reproduction of L-dopa-induced dyskinesia (LID

Figshare2017-12-22 更新30

In vivo safety profile in CIA mice treated with MFK902.

关节炎药物安全性

临床前药效评价

In vivo safety profile in CIA mice treated with MFK902.

NIAID Data Ecosystem60

Clinical parameters in the pilot study examining the efficacy of heme arginate (HA) and L-arginine (LA) in the db/db mouse model of type 2 diabetes.

糖尿病动物模型

临床前药效评价

Clinical parameters in the pilot study examining the efficacy of heme arginate (HA) and L-arginine (LA) in the db/db mouse model of type 2 diabetes.

NIAID Data Ecosystem40